Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
| Status: | Recruiting |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 9/2/2018 |
| Start Date: | January 2009 |
| End Date: | December 2024 |
Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes
Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due
to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an
contributes to the development of many of its complications. Multiple defects, e.g. impaired
insulin secretion and impaired insulin action, contribute to the development of the disease.
The aim of this study is to test the efficacy and durability of combination of drugs which
correct the defects that lead to the development of diabetes on achieving adequate and
durable control of blood sugar levels. Achieving adequate and durable control of blood sugar
will prevent many of diabetes complications.
to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an
contributes to the development of many of its complications. Multiple defects, e.g. impaired
insulin secretion and impaired insulin action, contribute to the development of the disease.
The aim of this study is to test the efficacy and durability of combination of drugs which
correct the defects that lead to the development of diabetes on achieving adequate and
durable control of blood sugar levels. Achieving adequate and durable control of blood sugar
will prevent many of diabetes complications.
Inclusion Criteria:
- subjects with type 2 diabetes diagnosed during the past 2 years,
- above 18 years of age,
- drug naive, or have been on metformin less than 3 months
Exclusion Criteria:
- subjects with type 1 diabetes or GAD positive subjects or subjects with long standing
diabetes (>2 years) or subjects who are not drug naive or have been on metformin more
than 3 months.
We found this trial at
1
site
San Antonio, Texas 78229
Principal Investigator: Ralph DeFronzo, MD
Phone: 210-567-2391
Click here to add this to my saved trials
